Expanding the human lifespan through peptide based innovation.
As the first publicly traded company focused exclusively on peptides and longevity, Vesalius offers an unparalleled opportunity to invest in the future of human health.
All products and services are grounded in cutting-edge biotechnology and regenerative medicine, backed by world-class research and clinical evidence.
Our board includes world-renowned scientists, medical experts, and biotech pioneers, ensuring that we stay ahead in research and innovation.
Our management team brings decades of experience in driving results for investors and scaling life-changing health technologies.
With a clear focus on peptide therapies, longevity and health span extension, Vesalius stands to transform both individual health outcomes and global healthcare markets.
Vesalius integrates personalized health assessments, peptide therapies, and longevity programs, delivering a holistic strategy that maximizes health span and vitality.
By 2030, 1 in 6 people globally will be over 60, increasing demand for aging therapies.
Chronic diseases account for 74% of global deaths, pushing demand for effective peptide treatments to improve outcomes.
The personalized medicine market is projected to reach $112 billion by 2030, driving demand for targeted peptide therapies.
Over 80 new peptide-based drugs entered clinical trials in the last 5 years, accelerating therapeutic possibilities.
In 2022, over 20 peptide drugs received fast-track approval, highlighting growing regulatory support and therapeutic value.
Wellness market worth $4.5 trillion in 2023 signals increased consumer interest in longevity and peptide-based health solutions.
.svg){kind=small}
